Background: Nine proteins were identified as putative profibrotic biomarkers in systemic sclerosis (SSc) and an unrelated fibrotic disease in a previously published proteomic study. As the majority of these proteins w...Background: Nine proteins were identified as putative profibrotic biomarkers in systemic sclerosis (SSc) and an unrelated fibrotic disease in a previously published proteomic study. As the majority of these proteins were orphans of commercially available antibodies, the nine proteins were investigated to determine whether binding peptide aptamers of the Stefin A quadruple mutant-Tracy variant (referred to as “affimers”) could be validated by enzyme linked immunosorbant assay (ELISA) to allow the quantification of these candidate biomarkers in the sera of SSc patients. Materials and Methods: Candidate biomarker peptides were analysed by high throughput affimer microarray to identify binding affimers. Two candidate biomarkers were prioritised, and binding affimers were expressed from genetically modified BL21 competent E. coli strains and purified. These affimers were used in indirect ELISA, and then sandwich ELISA formats against the candidate biomarker recombinant proteins osteonectin and pigment epi-thetlium-derived factor (PEDF). Results: 39 affimers were identified as binders for eight of the nine candidate biomarker peptides were by affimer microarray;six for osteonectin and eleven for PEDF. Two of the six and all eleven were able to recognize physiological concentrations (5 and 1 μg·ml﹣1) of osteonectin and PEDF, respectively by indirect ELISA. In sandwich ELISA format: two affimers were able to detect recombinant PEDF;however, the two affimers identified in indirect ELISA were unable to recognise recombinant osteonectin, and were thus hypothesised to bind to osteonectin at the same binding site. Discussion: SSc is currently an orphan of fully validated biomarkers, which is required for the development of stratified medicine in this field. This approach has laid the groundwork for an affimer based on multiplexed assay, to validate biomarkers in the sera of SSc patients in the future.展开更多
在中国经济转向创新驱动的背景下,科技成果转移转化工作为促进科技向生产力和经济发展转变发挥了关键作用。聚焦科技成果转移转化过程的“最初一公里”——概念验证(proof of concept,POC)及概念验证中心(proof of concept center,POCC...在中国经济转向创新驱动的背景下,科技成果转移转化工作为促进科技向生产力和经济发展转变发挥了关键作用。聚焦科技成果转移转化过程的“最初一公里”——概念验证(proof of concept,POC)及概念验证中心(proof of concept center,POCC)建设,通过详细回顾美国在这一领域的发展历程,特别是德什潘德中心和佐治亚理工创业实验室(VentureLab)的案例研究,揭示了POCC在支持早期科技创新和促进商业化方面成功经验及重要作用。美国POCC的运作模式和成功要素为理解如何帮助创业团队评估商业可行性提供了有价值的参考;基于对美国经验的分析,提出了一系列针对中国在POCC建设方面的策略和建议,包括发挥政府引导作用、融合多元主体和强化创新体系、发挥中国特色。这些建议旨在促进科技成果的商业化,加强大学、政府和企业之间的协同创新,从而推动科技创新不断面向国民经济主战场。展开更多
国产信创升级改造,通常更多关注产品的性能,认为产品性能符合要求就能满足国产化的需求,而忽视了产品和业务的匹配,极易出现应用程序崩溃、语法错误等问题。为解决此问题,本文提出了一种基于POC(Proof of Concept)测试的信创改造升级方...国产信创升级改造,通常更多关注产品的性能,认为产品性能符合要求就能满足国产化的需求,而忽视了产品和业务的匹配,极易出现应用程序崩溃、语法错误等问题。为解决此问题,本文提出了一种基于POC(Proof of Concept)测试的信创改造升级方法。首先,通过对现有信息系统现状的分析,明确了系统改造升级的规模和复杂度。在此基础上设计了比核心业务更为复杂的应用,并基于此应用分别进行了单产品测试、联合产品测试,最终形成测试的数据和结果。通过对比分析结果来辅助企业进行信创产品升级策略的制定。此方法可以有效的解决国产化产品和业务不匹配的问题。展开更多
文摘Background: Nine proteins were identified as putative profibrotic biomarkers in systemic sclerosis (SSc) and an unrelated fibrotic disease in a previously published proteomic study. As the majority of these proteins were orphans of commercially available antibodies, the nine proteins were investigated to determine whether binding peptide aptamers of the Stefin A quadruple mutant-Tracy variant (referred to as “affimers”) could be validated by enzyme linked immunosorbant assay (ELISA) to allow the quantification of these candidate biomarkers in the sera of SSc patients. Materials and Methods: Candidate biomarker peptides were analysed by high throughput affimer microarray to identify binding affimers. Two candidate biomarkers were prioritised, and binding affimers were expressed from genetically modified BL21 competent E. coli strains and purified. These affimers were used in indirect ELISA, and then sandwich ELISA formats against the candidate biomarker recombinant proteins osteonectin and pigment epi-thetlium-derived factor (PEDF). Results: 39 affimers were identified as binders for eight of the nine candidate biomarker peptides were by affimer microarray;six for osteonectin and eleven for PEDF. Two of the six and all eleven were able to recognize physiological concentrations (5 and 1 μg·ml﹣1) of osteonectin and PEDF, respectively by indirect ELISA. In sandwich ELISA format: two affimers were able to detect recombinant PEDF;however, the two affimers identified in indirect ELISA were unable to recognise recombinant osteonectin, and were thus hypothesised to bind to osteonectin at the same binding site. Discussion: SSc is currently an orphan of fully validated biomarkers, which is required for the development of stratified medicine in this field. This approach has laid the groundwork for an affimer based on multiplexed assay, to validate biomarkers in the sera of SSc patients in the future.
文摘在中国经济转向创新驱动的背景下,科技成果转移转化工作为促进科技向生产力和经济发展转变发挥了关键作用。聚焦科技成果转移转化过程的“最初一公里”——概念验证(proof of concept,POC)及概念验证中心(proof of concept center,POCC)建设,通过详细回顾美国在这一领域的发展历程,特别是德什潘德中心和佐治亚理工创业实验室(VentureLab)的案例研究,揭示了POCC在支持早期科技创新和促进商业化方面成功经验及重要作用。美国POCC的运作模式和成功要素为理解如何帮助创业团队评估商业可行性提供了有价值的参考;基于对美国经验的分析,提出了一系列针对中国在POCC建设方面的策略和建议,包括发挥政府引导作用、融合多元主体和强化创新体系、发挥中国特色。这些建议旨在促进科技成果的商业化,加强大学、政府和企业之间的协同创新,从而推动科技创新不断面向国民经济主战场。
文摘国产信创升级改造,通常更多关注产品的性能,认为产品性能符合要求就能满足国产化的需求,而忽视了产品和业务的匹配,极易出现应用程序崩溃、语法错误等问题。为解决此问题,本文提出了一种基于POC(Proof of Concept)测试的信创改造升级方法。首先,通过对现有信息系统现状的分析,明确了系统改造升级的规模和复杂度。在此基础上设计了比核心业务更为复杂的应用,并基于此应用分别进行了单产品测试、联合产品测试,最终形成测试的数据和结果。通过对比分析结果来辅助企业进行信创产品升级策略的制定。此方法可以有效的解决国产化产品和业务不匹配的问题。